Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors

被引:135
作者
Winter, Sherry L.
Bosnoyan-Collins, Lucine
Pinnaduwage, Dushanthi
Andrulis, Irene L. [1 ]
机构
[1] Mt Sinai Hosp, Fred A Litwin Ctr Canc Genet, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
[2] Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada
[3] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Div Epidemiol & Biostat, Toronto, ON M5G 1X5, Canada
[4] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada
[5] Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada
来源
NEOPLASIA | 2007年 / 9卷 / 10期
关键词
circadian clock; gene expression; Per1; Per2; BRCA1;
D O I
10.1593/neo.07595
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is a growing body of evidence implicating aberrant circadian clock expression in the development of cancer. Based on our initial experiments identifying a putative interaction between BRCA1 and the clock proteins Per1 and Per2, as well as the reported involvement of the circadian clock in the development of cancer, we have performed an expression analysis of the circadian clock genes Per1 and Per2 in both sporadic and familial primary breast tumors and normal breast tissues using real-time polymerase chain reaction. Significantly decreased levels of Per1 were observed between sporadic tumors and normal samples (P <.00001), as well as a further significant decrease between familial and sporadic breast tumors for both Per1 (P <.00001) and Per2 (P <.00001). Decreased Per1 was also associated with estrogen receptor negativity (53% vs 15%, P =.04). These results suggest a role for both Per1 and Per2 in normal breast function and show for the first time that deregulation of the circadian clock may be an important factor in the development of familial breast cancer. Aberrant expression of circadian clock genes could have important consequences on the transactivation of downstream targets that control the cell cycle and on the ability of cells to undergo apoptosis, potentially promoting carcinogenesis.
引用
收藏
页码:797 / 800
页数:4
相关论文
共 17 条
[1]  
Agresti A., 2005, INTRO CATEGORICAL DA
[2]   neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer [J].
Andrulis, IL ;
Bull, SB ;
Blackstein, ME ;
Sutherland, D ;
Mak, C ;
Sidlofsky, S ;
Pritzker, KPH ;
Hartwick, RW ;
Hanna, W ;
Lickley, L ;
Wilkinson, R ;
Qizilbash, A ;
Ambus, U ;
Lipa, M ;
Weizel, H ;
Katz, A ;
Baida, M ;
Mariz, S ;
Stoik, G ;
Dacamara, P ;
Strongitharm, D ;
Geddie, W ;
McCready, D .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1340-1349
[3]   Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers [J].
Chen, ST ;
Choo, KB ;
Hou, MF ;
Yeh, KT ;
Kuo, SJ ;
Chang, JG .
CARCINOGENESIS, 2005, 26 (07) :1241-1246
[4]   Night shift work, light at night, and risk of breast cancer [J].
Davis, S ;
Mirick, DK ;
Stevens, RG .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (20) :1557-1562
[5]   The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo [J].
Fu, LN ;
Pelicano, H ;
Liu, JS ;
Huang, P ;
Lee, CC .
CELL, 2002, 111 (01) :41-50
[6]   The circadian clock: Pacemaker and tumour suppressor [J].
Fu, LN ;
Lee, CC .
NATURE REVIEWS CANCER, 2003, 3 (05) :350-361
[7]   The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells [J].
Gery, S ;
Komatsu, N ;
Baldjyan, L ;
Yu, A ;
Koo, D ;
Koeffler, HP .
MOLECULAR CELL, 2006, 22 (03) :375-382
[8]   Circadian gene mPer2 overexpression induces cancer cell apoptosis [J].
Hua, Hui ;
Wang, Yueqi ;
Wan, Chaomin ;
Liu, Yanyou ;
Zhu, Bin ;
Yang, Chunlei ;
Wang, Xiaojia ;
Wang, Zhengrong ;
Cornelissen-Guillaume, Germaine ;
Halberg, Franz .
CANCER SCIENCE, 2006, 97 (07) :589-596
[9]   Characteristics associated with participation at various stages at the Ontario site of the Cooperative Family Registry for Breast Cancer Studies [J].
Knight, JA ;
Sutherland, HJ ;
Glendon, G ;
Boyd, NF ;
Andrulis, IL .
ANNALS OF EPIDEMIOLOGY, 2002, 12 (01) :27-33
[10]   The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 [J].
Lakhani, SR ;
van de Vijver, MJ ;
Jacquemier, J ;
Anderson, TJ ;
Osin, PP ;
McGuffog, L ;
Easton, DF .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2310-2318